With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.
Johnson & Johnson and Bayer's Xarelto made its way to the front of the new-age anticoagulant pack not long after hitting the U.S. market, gaining ground from rival Pradaxa to head what has since become a three-horse race. And that's ground its makers aren't ready to cede.
Chalk up a win for Bayer KGaA in its running battle in India over a compulsory license granted to Natco to produce a cheap knock-off of its cancer drug Nexavar. The drug is being sold in India but a high court there says that is as far as the Indian drugmaker can go with it for now.
German pharma giant Bayer got back-to-back bad news on two of its newest drugs, from two different countries, no less.
In the race to win FDA approval for a long-acting hemophilia A treatment, Novo Nordisk said its factor VIII therapy came through in a Phase III study, helping the Danish drugmaker play catchup in a three-way contest with Biogen Idec and Bayer.
The German drugmaker is feeling certain enough about a couple of potential hemophilia hits in its pipeline that it will spend nearly $700 million on new facilities in Germany that it says will add 500 jobs in its home country.
The CEO of the German drugmaker is pinning some numbers on the medium term; the Big 5 will help Bayer aim for an average of 8% annual growth in its pharma unit through 2016, Marijn Dekkers said Wednesday.
Bayer is gambling $700 million on the ultimate success of its new hemophilia drugs now in Phase III testing. That's about how much Bayer's growing healthcare division plans to spend as it boosts its manufacturing capacity at two sites in Germany.
Bayer and Onyx Pharmaceuticals' Nexavar has seen a lot of success as a liver cancer treatment, but as an adjuvant therapy for liver cancer, it could be awhile--if ever. On Tuesday, the drug missed its target in a Phase III trial, failing to meet the study's main goal of improving recurrence-free survival.
Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...